Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast CancerCompleted
NCT00773695Phase 2Updated Jan 9, 2023
Sponsor: Hoffmann-La Roche
Breast Cancer
Norway
Emicizumab in Acquired Hemophilia ACompleted
NCT04188639Phase 2Updated Jan 9, 2023
Sponsor: GWT-TUD GmbH
Hemophilia A, Acquired
Austria, Germany
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsCompleted
NCT02825940Phase 1Updated Jan 4, 2023
Sponsor: Hoffmann-La Roche
Neoplasms
China
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe AsthmaCompleted
NCT02918019Phase 2Updated Dec 28, 2022
Sponsor: Hoffmann-La Roche
Asthma
United States, Argentina, Belgium, Bulgaria, Canada +10 more
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.Completed
NCT00642577Phase 3Updated Dec 22, 2022
Sponsor: Hoffmann-La Roche
Colorectal Cancer
China
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyCompleted
NCT02141282Phase 2Updated Dec 19, 2022
Sponsor: AbbVie
Chronic Lymphocytic Leukemia
United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)Withdrawn
NCT05494619Phase 3Updated Dec 15, 2022
Sponsor: Hoffmann-La Roche
Guillain-Barré Syndrome
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1Completed
NCT02985866NAUpdated Dec 5, 2022
Sponsor: University of Virginia
Type1 Diabetes Mellitus
United States
Tocilizumab Plus a Short Prednisone Taper for GCACompleted
NCT03726749Phase 4Updated Dec 2, 2022
Sponsor: Massachusetts General Hospital
Giant Cell Arteritis
United States
Vemurafenib Plus Cobimetinib in Metastatic MelanomaTerminated
NCT02414750Phase 2Updated Nov 30, 2022
Sponsor: Netherlands Working Group on Immunotherapy of Oncology
Metastatic Melanoma
Netherlands
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)Completed
NCT02627274Phase 1Updated Nov 22, 2022
Sponsor: Hoffmann-La Roche
Solid Tumor · Breast Cancer · Cancer of Head and Neck
United States, Belgium, Canada, Denmark, France +4 more
Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaCompleted
NCT03271554N/AUpdated Nov 18, 2022
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
South Korea
Under and Over Rehabilitation StudyCompleted
NCT04490044NAUpdated Nov 18, 2022
Sponsor: Queen Mary University of London
Multiple Sclerosis
United Kingdom
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis BCompleted
NCT01519960Phase 3Updated Nov 18, 2022
Sponsor: Hoffmann-La Roche
Hepatitis B, Chronic
United States, Australia, Belgium, Bulgaria, China +7 more
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesCompleted
NCT00433589Phase 3Updated Nov 17, 2022
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Netherlands
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1Completed
NCT01597414Phase 2Updated Nov 17, 2022
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Elderly Metastatic Breast Cancer Population
Belgium, France, Italy, Netherlands, Poland +3 more
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal CancerCompleted
NCT01326000Phase 2Updated Nov 17, 2022
Sponsor: Hoffmann-La Roche
Colorectal Cancer
United States, Australia, Belgium, France, Germany +4 more
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompleted
NCT02847637Phase 3Updated Nov 16, 2022
Sponsor: Hoffmann-La Roche
Hemophilia A
United States, Australia, Costa Rica, France, Germany +9 more
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's DiseaseCompleted
NCT02394028Phase 3Updated Nov 16, 2022
Sponsor: Hoffmann-La Roche
Crohn Disease
United States, Argentina, Australia, Austria, Belgium +28 more
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaCompleted
NCT02257567Phase 1, Phase 2Updated Nov 14, 2022
Sponsor: Hoffmann-La Roche
Lymphoma
United States, Australia, Canada, Czechia, France +8 more
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminated
NCT03784599Phase 2Updated Nov 10, 2022
Sponsor: The Netherlands Cancer Institute
Carcinoma, Non-Small-Cell Lung
Netherlands
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerActive Not Recruiting
NCT04186013Phase 2Updated Oct 26, 2022
Sponsor: Spanish Oncology Genito-Urinary Group
Bladder Cancer
Spain
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19Completed
NCT04709835Phase 2Updated Oct 26, 2022
Sponsor: Hoffmann-La Roche
COVID-19
Canada, Greece, Ireland, Latvia, Spain +1 more
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACSCompleted
NCT02525939Phase 3Updated Oct 12, 2022
Sponsor: DalCor Pharmaceuticals
Acute Coronary Syndrome
United States, Argentina, Australia, Austria, Belgium +27 more
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment RegimenCompleted
NCT02419742Phase 4Updated Oct 12, 2022
Sponsor: Hoffmann-La Roche
Breast Cancer
India

Previous page Next page